ADMAADMA Biologics Inc

Ticker: ADMA | Price: $12.81 | Today's Change: +22.23%

---

What Happened

ADMA Biologics filed an 8-K with the SEC on November 4, 2026 (Items 2.02 and 9.01) disclosing its financial results for the third quarter of fiscal year 2026. The company reported revenue of $371.0 million for Q3 FY2026, a figure that underscores a dramatic scale-up from the $10.2 million in revenues recorded as recently as Q1 FY2021. Net income came in at $26.9 million, with basic earnings per share of $0.41 and diluted EPS of $0.40. The scale of these results makes this a highly material disclosure.

---

Why It Matters

The headline numbers represent a business in a fundamentally different competitive position than it occupied just a few years ago:

• Operating income of $128.7 million in a single quarter signals that ADMA's plasma-derived immunoglobulin operations have reached a level of industrial maturity and margin leverage that is difficult to ignore.
• Net income of $26.9 million confirms genuine bottom-line profitability — not just top-line growth — an important distinction for a company that spent years building out its manufacturing and commercial infrastructure.
• EPS of $0.41 (basic) / $0.40 (diluted) gives investors a concrete per-share earnings anchor against the current stock price, which is trading at $12.81 after today's sharp 22%+ move.
• The gap between operating income ($128.7M) and net income ($26.9M) warrants attention — investors will want to understand what below-the-line items (interest expense, taxes, or one-time charges) account for the difference, details that will be elaborated in the full financial statements attached to this filing.

For context, this report follows StockWatch's initiating coverage on ADMA published September 28, 2026 — the Q3 results now provide the first major earnings data point since that coverage was established.

---

Analysis

Today's market reaction — a jump of more than 22% — reflects the magnitude by which these results appear to have exceeded near-term expectations. The revenue figure of $371 million for a single quarter is striking for a company of ADMA's size, and the operating income margin implied by these figures suggests the business has strong operating leverage at current production volumes.

A few key dynamics to watch going forward:

1. Margin sustainability: Operating income of $128.7M on revenue of $371M implies an operating margin of approximately 34.7%. Sustaining margins at this level will depend heavily on plasma collection costs, FDA compliance continuity, and pricing dynamics in the immunoglobulin market.
2. The operating-to-net income gap: With $128.7M in operating income but only $26.9M in net income, there is clearly a significant below-the-line cost structure — likely reflecting debt service, taxes, or non-cash items. Understanding this bridge will be critical for modeling future free cash flow.
3. Revenue trajectory: The comparison to Q1 FY2021's $10.2M in revenues highlights how rapidly this business has scaled. Whether that trajectory continues, moderates, or accelerates is the central question for the investment thesis.
4. Guidance and commentary: This 8-K flags the results but does not itself contain forward guidance. Investors should monitor any accompanying earnings call or press release for management's commentary on Q4 FY2026 and beyond.

The stock's move today suggests the market is reassessing ADMA's earnings power in light of these results. The fundamental question — whether the operational performance disclosed here is repeatable and extendable — remains open and will be shaped by the detail in the full financial statements and any forward-looking statements from management.

---

Disclaimer

This report is a news and informational analysis based solely on data extracted from ADMA Biologics' SEC filing dated November 4, 2026, and publicly available market data. It does not constitute investment advice, a solicitation to buy or sell any security, or an equity research recommendation of any kind. No rating or price target is issued or implied herein. Readers should conduct their own due diligence and consult a qualified financial professional before making any investment decisions. Past performance and historical results are not indicative of future outcomes.

Existing Coverage

StockWatch has full coverage on ADMA, published 2026-09-28. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-11-04. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1368514/000114036126041959/ef20084542_8k.htm